Dennis L. Murphy

Dennis L. Murphy's AcademicInfluence.com Rankings

Dennis L. Murphy

Biology

#2690

World Rank

#4245

Historical Rank

Neuroscience

#236

World Rank

#250

Historical Rank

Biochemistry

#228

World Rank

#286

Historical Rank

biology Degrees

Download Badge

Biology

Dennis L. Murphy's Degrees

Doctorate Psychiatry Stanford University

Why Is Dennis L. Murphy Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dennis L. Murphy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. (2006) (1175)
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. (1998) (706)
Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. (1990) (594)
Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531 (2006) (561)
Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. (1999) (549)
Primary Structure of the Human Platelet Serotonin Uptake Site: Identity with the Brain Serotonin Transporter (1993) (541)
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. (1986) (500)
Organization of the human serotonin transporter gene (2005) (490)
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. (1998) (486)
Cognitive processes in depression. (1981) (482)
Serotonin transporter: gene, genetic disorders, and pharmacogenetics. (2004) (439)
Sensation seeking and its biological correlates. (1980) (438)
Targeting the murine serotonin transporter: insights into human neurobiology (2008) (435)
Effort and cognition in depression. (1982) (390)
The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. (1976) (379)
Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. (1987) (364)
Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. (1983) (355)
Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time (1976) (354)
Impaired Stress-Coping and Fear Extinction and Abnormal Corticolimbic Morphology in Serotonin Transporter Knock-Out Mice (2007) (347)
Reduced Monoamine Oxidase Activity in Blood Platelets from Schizophrenic Patients (1972) (338)
Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. (2000) (334)
Obsessive-compulsive disorder and serotonin: Is there a connection? (1985) (327)
Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression (2003) (321)
Abnormal anxiety‐related behavior in serotonin transporter null mutant mice: the influence of genetic background (2003) (317)
Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. (1972) (316)
Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. (1997) (316)
Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. (1987) (306)
Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. (1988) (300)
Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. (1997) (296)
Obsessive–compulsive disorder symptom dimensions show specific relationships to psychiatric comorbidity (2005) (296)
Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis (2018) (294)
Mice Lacking the Serotonin Transporter Exhibit 5-HT1A Receptor-Mediated Abnormalities in Tests for Anxiety-like Behavior (2003) (294)
A genetic association for cigarette smoking behavior. (1999) (293)
Reduced Monoamine Oxidase Activity in Platelets: A Possible Genetic Marker for Vulnerability to Schizophrenia (1973) (285)
Evaluation of Antidepressant-related Behavioral Responses in Mice Lacking the Serotonin Transporter (2002) (282)
Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture (2013) (280)
What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression (2007) (271)
Excessive Activation of Serotonin (5-HT) 1B Receptors Disrupts the Formation of Sensory Maps in Monoamine Oxidase A and 5-HT Transporter Knock-Out Mice (2001) (261)
Genome-wide association study of obsessive-compulsive disorder (2013) (256)
Reduced aggression in mice lacking the serotonin transporter (2002) (251)
Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. (1988) (249)
High plasma norepinephrine levels in patients with major affective disorder. (1982) (247)
Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. (1984) (247)
Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. (1992) (246)
Genome-Wide Association Study in Obsessive-Compulsive Disorder: Results from the OCGAS (2014) (244)
Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. (1969) (243)
Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. (1977) (243)
Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. (2005) (235)
Regular Induction of Hypomania by L-Dopa in “Bipolar” Manic-depressive Patients (1971) (235)
Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. (1991) (230)
Is obsessive–compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective (2011) (224)
Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. (1993) (217)
Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. (1990) (215)
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems (2008) (214)
Age-related changes in sleep in depressed and normal subjects (1981) (213)
Barrel Pattern Formation Requires Serotonin Uptake by Thalamocortical Afferents, and Not Vesicular Monoamine Release (2001) (213)
Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. (2003) (212)
Influence of affective states and psychoactive drugs on verbal learning and memory. (1973) (209)
Lithium response in unipolar versus bipolar depression. (1972) (209)
Monoamine oxidase : structure, function, and altered functions (1979) (207)
The sleep of patients with obsessive-compulsive disorder. (1982) (207)
Hoarding in obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. (2007) (205)
Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder (1999) (199)
Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. (1999) (199)
Genetic perspectives on the serotonin transporter (2001) (198)
Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. (1977) (190)
Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter (2005) (189)
Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls (1982) (187)
Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. (1985) (187)
Regional Differences in Extracellular Dopamine and Serotonin Assessed by In Vivo Microdialysis in Mice Lacking Dopamine and/or Serotonin Transporters (2004) (185)
Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. (1989) (184)
Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. (1992) (183)
Biogenic amine-related enzymes and personality variations in normals (1977) (182)
L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. (1970) (182)
Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions (2008) (180)
Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study (2009) (179)
Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice. (2010) (176)
Neurological and neuropsychological studies of patients with obsessive-compulsive disorder. (1983) (173)
Fluoxetine in the Treatment of Premenstrual Dysphoria (1997) (172)
L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. (1987) (172)
Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. (2009) (171)
Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. (1987) (171)
PSYCHOLOGICAL CORRELATES OF MONOAMINE OXIDASE ACTIVITY IN NORMALS (1978) (170)
Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. (2001) (169)
Multiple rare SAPAP3 missense variants in trichotillomania and OCD (2009) (169)
Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. (1993) (168)
Unipolar and bipolar affective illness. Differences in clinical characteristics accompanying depression. (1971) (168)
The Manic-State Rating Scale: Scale Construction, Reliability, and Validity (1971) (167)
Analyzing grooming microstructure in neurobehavioral experiments (2007) (166)
Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. (2008) (165)
Familiality of Factor Analysis-Derived YBOCS Dimensions in OCD-Affected Sibling Pairs from the OCD Collaborative Genetics Study (2007) (163)
Serotonin and central nervous system function. (1973) (161)
Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences. (1978) (160)
Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. (2007) (158)
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. (1998) (158)
Platelet monoamine oxidase activity in schizophrenia: a review of the data. (1979) (156)
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. (2012) (154)
Platelet 5-HT uptake and release stopped rapidly by formaldehyde (1975) (154)
A human serotonin transporter mutation causes constitutive activation of transport activity. (2003) (151)
Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. (1996) (148)
An investigation of traumatic life events and obsessive-compulsive disorder. (2007) (146)
Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q (2006) (145)
Characterizing the hoarding phenotype in individuals with OCD: associations with comorbidity, severity and gender. (2008) (145)
Platelet and Plasma Amine Oxidase Activity in Alcoholic Individuals (1978) (143)
The "switch process" in manic-depressive illness. I. A systematic study of sequential behavioral changes. (1972) (143)
Changes in α- and β-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants (1982) (140)
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. (2007) (138)
Further development of YBOCS dimensions in the OCD Collaborative Genetics Study: Symptoms vs. categories (2008) (138)
A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. (2009) (137)
Mood-state-dependent retrieval of verbal associations. (1977) (136)
Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. (1971) (135)
Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. (1989) (134)
Intravenous nicotine in Alzheimer's disease: a pilot study (2004) (133)
Monamine oxidase in schizophrenia and other behavioral disorders. (1974) (132)
Human platelet monoamine oxidase changes during the menstrual cycle. (1974) (132)
Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. (1980) (129)
Treatment of Hyperactive Children With Monoamine Oxidase Inhibitors: I. Clinical Efficacy (1985) (127)
Platelet Mao Activity and Evoked Potentials in the Identification of Subjects Biologically at Risk for Psychiatric Disorders (1979) (126)
Do traumatic events influence the clinical expression of compulsive hoarding? (2007) (126)
Isolation of a cDNA encoding the human brain serotonin transporter (2005) (125)
THE EFFECTS OF CHRONIC REGIMENS OF CLORGYLINE AND PARGYLINE ON MONOAMINE METABOLISM IN THE RAT BRAIN (1979) (125)
Motor cortex excitability correlates with an anxiety-related personality trait (2001) (123)
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. (2015) (123)
Anxiogenic effects of m-CPP in patients with panic disorder: Comparison to caffeine's anxiogenic effects (1991) (123)
High-dose selegiline in treatment-resistant older depressive patients. (1994) (121)
Serotonin in Major Psychiatric Disorders (1990) (121)
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder (1995) (121)
Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? (1995) (121)
The switch process from depression to mania: relationship to drugs which alter brain amines. (1970) (120)
Assessing clinical characteristics of the manic state. (1971) (119)
Ferrous‐Citrate Complex and Nigral Degeneration: Evidence for Free‐radical Formation and Lipid Peroxidation a (1994) (117)
Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder (1991) (116)
Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. (1992) (116)
Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. (2002) (116)
Possible development of the serotonin syndrome in man. (1982) (116)
The dexamethasone suppression test in patients with primary obsessive-compulsive disorder (1982) (115)
Vulnerability to mild predator stress in serotonin transporter knockout mice (2006) (115)
The "switch process" in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. (1972) (115)
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans (1974) (114)
A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. (1992) (113)
Biochemical correlates of personality traits in normals: An exploratory study (1983) (111)
Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. (2014) (109)
Suicide attempts, platelet monoamine oxidase and the average evoked response (1977) (109)
A Controlled Comparison of Adjuvant Lithium Carbonate or Thyroid Hormone in Clomipramine‐Treated Patients with Obsessive‐Compulsive Disorder (1991) (108)
Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative (2002) (107)
Absence of Thermal Hyperalgesia in Serotonin Transporter-Deficient Mice (2003) (107)
Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder (2001) (107)
Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment (1975) (107)
High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. (1983) (106)
Pharmacologic modelling of Alzheimer's disease (1986) (105)
A preliminary investigation of the lifetime prevalence of anorexia and bulimia nervosa in patients with obsessive compulsive disorder. (1992) (105)
Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. (1993) (105)
Involvement of insula and cingulate cortices in control and suppression of natural urges. (2009) (105)
Quantitative studies of norepinephrine uptake by synaptosomes. (1968) (103)
A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP (1993) (103)
Gender-Dependent Modulation of Brain Monoamines and Anxiety-like Behaviors in Mice with Genetic Serotonin Transporter and BDNF Deficiencies (2006) (103)
Depression, elation, and lithium carbonate responses in manic patient subgroups. (1974) (102)
Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems. (1990) (101)
Leukocytosis during lithium treatment. (1971) (101)
Physostigmine induction of depressive symptomatology in normal human subjects (1981) (101)
Mood-incongruent psychotic features in bipolar disorder: familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. (2007) (100)
Psychiatric vulnerability, monoamine oxidase, and the average evoked potential. (1980) (100)
Neuroimaging of neuronal circuits involved in tic generation in patients with Tourette syndrome (2007) (99)
Cognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans (1997) (97)
Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. (1989) (97)
Are paranoid schizophrenics biologically different from other schizophrenics? (1978) (96)
Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with alzheimer's disease (1990) (95)
Reduced MAO activity in first-degree relatives of individuals with bipolar affective disorders. A preliminary report. (1977) (94)
Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid (1979) (94)
Food intake, neuroendocrine and temperature effects of 8-OHDPAT in the rat. (1988) (92)
Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. (2002) (92)
Multiple-dose arecoline infusions in Alzheimer's disease. (1988) (92)
Effects of Mild Early Life Stress on Abnormal Emotion-related Behaviors in 5-HTT Knockout Mice (2007) (90)
Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. (1991) (90)
Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment (1980) (90)
Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity (2013) (90)
A Large Case–Control Study of Common Functional SLC6A4 and BDNF Variants in Obsessive–Compulsive Disorder (2007) (90)
Catecholamines and mania: The effect of alpha‐methyl‐para‐tyrosine on manic behavior and catecholamine metabolism (1971) (89)
Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. (1989) (89)
Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. (1997) (89)
Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. (1991) (88)
The brain serotonergic system in the affective disorders. (1978) (87)
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users (1999) (87)
Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin. (1982) (87)
Obsessive—Compulsive Disorder as a 5-HT Subsystem-Related Behavioural Disorder (1989) (87)
Heterogeneity of human whole blood platelet subpopulations. III. Density-dependent differences in subcellular constituents. (1984) (87)
Obsessive–compulsive disorder: subclassification based on co-morbidity (2008) (86)
Ethanol Inhibits Clearance of Brain Serotonin by a Serotonin Transporter-Independent Mechanism (2006) (86)
Deprenyl in Parkinson disease (1981) (85)
The serotonin 5-HT2A receptor agonist TCB-2: a behavioral and neurophysiological analysis (2010) (83)
Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. (2001) (83)
Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. (2011) (83)
Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans (1996) (83)
Developmental disruption of serotonin transporter function impairs cerebral responses to whisker stimulation in mice. (2005) (83)
Stimulation by lithium of monoamine uptake in human platelets. (1969) (82)
Effects of serotonergic agents on food-restriction-induced hyperactivity (1996) (82)
Ethanol-related behaviors in serotonin transporter knockout mice. (2006) (82)
Symptoms of eating disorders in patients with obsessive-compulsive disorder. (1991) (81)
New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. (1984) (81)
Obsessive compulsive disorder: comorbid conditions. (1994) (80)
Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. (1970) (80)
Impaired smooth pursuit eye movement: vulnerability marker for schizotypal personality disorder in a normal volunteer population. (1984) (80)
Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts (2010) (79)
Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. (2007) (79)
Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. (1997) (79)
Decreased neuronal inhibition in cerebral cortex in obsessive compulsive disorder on transcranial magnetic stimulation (1998) (79)
Platelet Monoamine Oxidase Activity Correlates with Social Affiliative and Agonistic Behaviors in Normal Rhesus Monkeys (1979) (78)
Plasma cortisol responses to clonidine in depressed patients and controls. Evidence for a possible alteration in noradrenergic-neuroendocrine relationships. (1984) (78)
Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. (1991) (78)
Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers (2004) (77)
Normal CSF oxytocin and NPY levels in OCD (1999) (77)
Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice (2007) (77)
5-HT2A/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter (2005) (76)
Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. (1984) (76)
Aldosterone and sodium response to lithium administration in man. (1969) (76)
Role of the serotonin transporter gene in temperament and character. (1999) (76)
Growth Hormone Response to Clonidine in Obsessive-Compulsive Patients (1983) (76)
Long-term cortisol treatment impairs behavioral and neuroendocrine responses to 5-HT1 agonists in the rat. (1989) (75)
Are serotonin transporter knockout mice ‘depressed’?: hypoactivity but no anhedonia (2006) (75)
Platelet monoamine oxidase activity in acute schizophrenia. (1975) (75)
Inhibition by lithium of prostaglandin E1 and norepinephrine effects on cyclic adenosine monophosphate production in human platelets (1973) (75)
Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. (1989) (74)
Low platelet monoamine oxidase activity and schizophrenia. (1976) (73)
Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. (1992) (73)
Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. (1999) (71)
Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. (2007) (71)
Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain (2004) (71)
The psychopharmacological treatment of obsessive-compulsive disorder: a review. (1981) (71)
Reduced Sensitivity to Glucocorticoid Feedback and Reduced Glucocorticoid Receptor mRNA Expression in the Luteal Phase of the Menstrual Cycle (1997) (70)
Parents of patients with obsessive-compulsive disorder (1983) (69)
Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells. (1976) (67)
The effect of 8-OH-DPAT on temperature in the rat and its modification by chronic antidepressant treatments (1988) (67)
Differential inhibitory noradrenergic responses to clonidine in 25 depressed patients and 25 normal control subjects. (1984) (66)
Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. (1982) (66)
Domain interplay concept in animal models of neuropsychiatric disorders: A new strategy for high-throughput neurophenotyping research (2008) (66)
Medial Hypothalamic 5-Hydroxytryptamine (5-HT)1A Receptors Regulate Neuroendocrine Responses to Stress and Exploratory Locomotor Activity: Application of Recombinant Adenovirus Containing 5-HT1A Sequences (2004) (66)
Pharmacologic models of anxiety. (1983) (65)
A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. (1990) (65)
Working memory as assessed by subject-ordered tasks in patients with obsessive-compulsive disorder. (1995) (65)
Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice (2007) (65)
Cooperation between Mast Cells and Neurons Is Essential for Antigen-Mediated Bronchoconstriction1 (2009) (65)
Chronic effects of a monoamine oxidase-inhibiting antidepressant: decreases in functional alpha-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3': 5'- monophosphate systems in rat brain (1982) (65)
Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. (1992) (65)
Antidepressants and alpha 2-adrenergic autoreceptor desensitization. (1981) (65)
A pharmacological analysis of mice with a targeted disruption of the serotonin transporter (2007) (64)
Prediction of antidepressant responses to lithium. (1978) (64)
Effect of L-DOPA on depression. (1969) (64)
The "switch process" in manic-depressive illness. 3. Theoretical implications. (1972) (64)
Association of SLC6A4 variants with obsessive-compulsive disorder in a large multi-center US family study (2009) (64)
Cellular localization and expression of the serotonin transporter in mouse brain (1997) (64)
Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice (2008) (63)
Use of serotonergic agents in the clinical assessment of central serotonin function. (1986) (63)
Regulation of G proteins by chronic antidepressant drug treatment in rat brain: tricyclics but not clorgyline increase Go alpha subunits. (1991) (63)
The effects of acute scopolamine in geriatric depression. (1988) (62)
A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. (1992) (62)
Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: a new model approach. (2000) (61)
Encoding-imagery specificity in alcohol state-dependent learning. (1976) (61)
Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. (1994) (60)
Lithium concentration by the thyroid. (1970) (60)
Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder. (1996) (60)
Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls (1993) (60)
Advances in the neurobiology of anxiety disorders (1996) (60)
Segregation and linkage studies of plasma dopamine-beta-hydroxylase (DBH), erythrocyte catechol-O-methyltransferase (COMT), and platelet monoamine oxidase (MAO): possible linkage between the ABO locus and a gene controlling DBH activity. (1982) (60)
Possible subsensitization of alpha2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients (1982) (59)
Reduced programmed cell death in brains of serotonin transporter knockout mice (2003) (59)
Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation (1979) (59)
Differential neuroendocrine responses to the 5-HT agonist m-chlorophenylpiperazine in Fawn-Hooded rats relative to Wistar and Sprague-Dawley rats. (1988) (59)
CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. (1987) (58)
Levodopa: Alterations in behavior (1971) (58)
The hoarding dimension of OCD: psychological comorbidity and the five-factor personality model. (2006) (58)
Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. (1997) (58)
Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain (1989) (58)
BDNF in Anxiety and Depression (2006) (58)
Corticotropin-releasing factor: a marked circadian rhythm in primate cerebrospinal fluid peaks in the evening and is inversely related to the cortisol circadian rhythm. (1987) (58)
Functional SLITRK1 var321, varCDfs and SLC6A4 G56A variants and susceptibility to obsessive-compulsive disorder (2006) (58)
Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive–compulsive disorder (OCD): behavioral and biological results (1998) (57)
Physiological effects of high dose naloxone administration to normal adults. (1982) (57)
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder (2008) (57)
The Importance of Cognitive Phenotypes in Experimental Modeling of Animal Anxiety and Depression (2007) (57)
Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors (2005) (57)
Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin (2004) (55)
Functional subsensitivity of alpha 2-adrenoceptors accompanies reductions in yohimbine binding after clorgyline treatment. (1982) (55)
Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity. (1976) (55)
Induction of antioxidative and antiapoptotic thioredoxin supports neuroprotective hypothesis of estrogen (2003) (55)
Lack of evidence for huntington's disease-like cognitive dysfunction in obsessive-compulsive disorder (1993) (55)
Gene structure and 5'-flanking regulatory region of the murine serotonin transporter. (1997) (54)
Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. (1993) (54)
Obsessive-compulsive characteristics in patients with idiopathic spasmodic torticollis (1992) (54)
Serotonin and platelet function in Duchenne muscular dystrophy. (1973) (54)
Cord blood amine oxidase activities relate to arousal and motor functioning in human newborns. (1981) (53)
Marked Amine and Amine Metabolite Changes in Norrie Disease Patients with an X‐Chromosomal Deletion Affecting Monoamine Oxidase (1990) (53)
Use of the Dexamethasone Suppression Test in Clinical Psychiatry (1981) (53)
CSF 5-HIAA and family history of antisocial personality disorder in newborns. (1997) (52)
Neuroanatomically based approaches to obsessive-compulsive disorder. Neurosurgery and transcranial magnetic stimulation. (2000) (52)
Magnesium reversal of lithium inhibition of beta-adrenergic and muscarinic receptor coupling to G proteins. (1991) (52)
Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters (2011) (51)
Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl (1986) (51)
Co-release of ACTH and beta-endorphin immunoreactivity in human subjects in response to central cholinergic stimulation. (1983) (50)
Eye-blink rates and platelet monoamine oxidase activity in chronic schizophrenic patients. (1980) (50)
miR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells. (2013) (50)
A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers (1991) (50)
D-Amphetamine in obsessive-compulsive disorder (2004) (49)
Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in nonhuman primates. (1988) (49)
Serotonin and externalizing behavior in young children (1999) (49)
Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. (1992) (49)
Monoamine oxidase-inhibiting antidepressants. A clinical update. (1984) (49)
A comparison of feeding and locomotion responses to serotonin agonists in three rat strains (1988) (49)
Consideration of the BDNF gene in relation to two phenotypes: hoarding and obesity. (2011) (49)
Platelet monoamine oxidase, plasma dopamine-beta-hydroxylase and attention in a "biochemical high risk" sample. (1978) (49)
Down's Syndrome: Transport, Storage, and Metabolism of Serotonin in Blood Platelets (1972) (49)
Prediction of imipramine antidepressant response by a one-day dextro-amphetamine trial. (1978) (49)
Excretion of 17-OHCS in unipolar and bipolar depressed patients. (1972) (49)
High-dose naloxone affects task performance in normal subjects (1983) (48)
Menstrual Cycle and Ovarian Hormone Effects on Plasma and Platelet Monoamine Oxidase (MAO) and Plasma Dopamine‐Beta‐Hydroxylase (DBH) Activities in the Rhesus Monkey (1975) (48)
A screen of SLC1A1 for OCD‐related alleles (2010) (48)
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. (1998) (48)
Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. (2002) (48)
Behavioral responses to intravenous meta-chlorophenyl- piperazine in patients with seasonal affective disorder and control subjects before and after phototherapy (1994) (48)
Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. (1985) (48)
Low platelet monoamine oxidase activity and chronic marijuana use. (1978) (47)
Naloxone Reduces Food Intake in Humans (1985) (47)
Platelet monoamine oxidase in chronic schizophrenic patients. (1978) (47)
Demonstration and evaluation of apparent cytoplasmic and vesicular serotonin compartments in human platelets. (1977) (47)
Idiosyncratic patterns of learning and word association during mania. (1971) (47)
Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice (2009) (47)
Hormonal responses to the administration of m-chlorophenylpiperazine in patients with seasonal affective disorder and controls (1995) (47)
Biological markers in obsessive-compulsive and affective disorders. (1984) (46)
SERT Ileu425Val in autism, Asperger syndrome and obsessive–compulsive disorder (2008) (46)
Functional and biochemical evidence for altered serotonergic function in the Fawn-Hooded rat strain (1994) (46)
Platelet Serotonin of Hyperactive School Age Boys (1974) (46)
Cross-sectional and longitudinal comparisons of bipolar and unipolar depressed groups on the MMPI. (1976) (45)
The regular and light–dark Suok tests of anxiety and sensorimotor integration: utility for behavioral characterization in laboratory rodents (2008) (45)
Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium (1995) (45)
Attenuation of food-restriction-induced running by chronic fluoxetine treatment. (1993) (44)
Imipramine and lithium effects of biogenic amine transport in depressed and manic-depressed patients. (1970) (44)
Smooth pursuit eye movement disorder and its psychobiologic correlates in unmedicated schizophrenics (1986) (44)
Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals. (1996) (44)
Intellectual Function in Primary Affective Disorder (1982) (44)
Smooth pursuit eye tracking impairment: relation to other 'markers' of schizophrenia and psychologic correlates. (1982) (43)
Behavioral effects of naloxone infusion in obsessive-compulsive disorder (1996) (43)
Serotonin transporter candidate gene studies in affective disorders and personality: promises and potential pitfalls (1998) (43)
Monoamine Oxidase in Chronic Schizophrenia (1977) (43)
Catecholamine receptor function in depressed patients. (1974) (43)
The developing use of heterozygous mutant mouse models in brain monoamine transporter research. (2007) (43)
Intravenous nicotine in a patient with Alzheimer's disease. (1986) (42)
Characterization of SLITRK1 Variation in Obsessive-Compulsive Disorder (2013) (42)
Sex-specific clinical correlates of hoarding in obsessive-compulsive disorder. (2008) (42)
Blepharospasm and Obsessive‐Compulsive Disorder (1992) (42)
Amine precursors, amines, and false neurotransmitters in depressed patients. (1972) (42)
Whole genome association analysis of treatment response in obsessive-compulsive disorder (2015) (42)
The Effects of Testosterone on Plasma and Platelet Monoamine Oxidase (MAO) and Plasma Dopamine‐&bgr;‐Hydroxylase (DBH) Activities in the Male Rhesus Monkey (1976) (42)
Increased mRNA for corticotrophin releasing hormone in the amygdala of fawn-hooded rats: a potential animal model of anxiety. (1994) (42)
Lack of Cross-Tolerance for Hypophagia Induced by DOI versus m-CPP Suggests Separate Mediation by 5-HT2A and 5-HT2C Receptors, Respectively (1995) (41)
The dexamethasone suppression test as a measure of hypothalamic-pituitary feedback sensitivity and its relationship to behavioral arousal. (1981) (41)
Increased gene expression of diacylglycerol kinase η in bipolar disorder. (2010) (41)
Differential effects of long-term lithium and carbamazepine administration on Gsα and Giα protein in rat brain (1991) (41)
Sodium balance and distribution in lithium carbonate therapy. (1970) (41)
Attenuation of hypercortisolemia in fawn-hooded rats by antidepressant drugs. (1993) (41)
The behavioral toxicity of monoamine oxidase-inhibiting antidepressants. (1977) (41)
Low platelet monoamine oxidase and vulnerability to schizophrenia. (1975) (41)
Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive‐compulsive disorder with compulsive hoarding (2008) (40)
Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice (2011) (40)
Muscarinic cholinergic influences on ACTH and β-endorphin release mechanisms in human subjects (1981) (40)
Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients (1998) (40)
Serotonin and Thermoregulation (1995) (39)
Perspectives on genetic animal models of serotonin toxicity (2008) (39)
Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex. (1990) (38)
Parents of high risk subjects defined by levels of monoamine oxidase activity. (1980) (38)
Primary affective disorder: MMPI differences between unipolar and bipolar depressed subjects. (1973) (38)
Cholinomimetic-induced co-release of prolactin and beta-endorphin in man. (1982) (38)
Phenylacetic acid excretion in schizophrenia and depression: the origins of PAA in man. (1984) (38)
Dexamethasone fails to suppress beta-endorphin plasma concentrations in humans and rhesus monkeys. (1980) (37)
Adult neurogenesis in serotonin transporter deficient mice (2007) (37)
MONOAMINE OXIDASE IN SCHIZOPHRENIA AND OTHER BEHAVIORAL DISORDERS (1975) (36)
Light and propranolol suppress the nocturnal elevation of serotonin in the cerebrospinal fluid of rhesus monkeys. (1983) (36)
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. (1982) (36)
PLATELET AND PLASMA AMINE OXIDASE INHIBITION AND URINARY AMINE EXCRETION CHANGES DURING PHENELZINE TREATMENT (1977) (36)
Effects of antidepressants and other psychotropic drugs on melatonin release and pineal gland function. (1986) (36)
Hoarding in Children and Adolescents with Obsessive-Compulsive Disorder. (2014) (36)
Symptom overlap between OCD and bulimia nervosa (1995) (36)
Non-linear association between the serotonin transporter promoter polymorphism and neuroticism: a caution against using extreme samples to identify quantitative trait loci. (1999) (36)
CONSEQUENCES OF ENGINEERED AND SPONTANEOUS GENETIC ALTERATIONS OF THE 5-HT TRANSPORTER IN MICE, MEN, AND WOMEN (1999) (36)
Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. (2009) (35)
Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. (1986) (35)
Naloxone and Alzheimer's disease. Cognitive and behavioral effects of a range of doses. (1986) (35)
A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. (1990) (35)
Cognitive effects of l-deprenyl in Alzheimer's disease (2004) (35)
Differential effects of long-term antidepressant treatments on 8-OHDPAT-induced increases in plasma prolactin and corticosterone in rats. (1988) (35)
Biological and behavioral consequences of alterations in monoamine oxidase activity. (1980) (34)
β-Endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action (1990) (34)
Seasonality associated with the serotonin transporter promoter repeat length polymorphism. (1999) (34)
Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: Evidence for a serotonin receptor mediated mechanism of action in humans (2004) (34)
The Catecholamines: Possible Role in Affect, Mood, and Emotional Behavior in Man and Animals (1975) (34)
5HTTLPR: White Knight or Dark Blight? (2013) (34)
Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain (1979) (33)
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). (1998) (33)
Genome-wide association study of obsessive-compulsive disorder (2013) (33)
Quantitative evaluation of the loss of human platelet dense bodies following stimulation by thrombin or A23187. (1977) (33)
Monoamine oxidase in man: enzyme characteristics in platelets, plasma, and other human tissues. (1974) (33)
A Large Case–Control Study of Common Functional SLC6A4 and BDNF Variants in Obsessive–Compulsive Disorder (2008) (33)
Growth hormone response to clonidine unchanged by chronic clorgyline treatment (1982) (33)
l-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects (1974) (33)
TRH stimulation test in dementia of the Alzheimer type and elderly controls (1985) (32)
Functional subsensitivity of 5-hydroxytryptamine1C or alpha 2 adrenergic heteroreceptors mediating clonidine-induced growth hormone release in the Fawn-Hooded rat strain relative to the Wistar rat strain. (1992) (32)
Serotonin hypothesis of winter depression: behavioral and neuroendocrine effects of the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects (1999) (32)
Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. (1984) (32)
Plasma catecholamines and their metabolites in obsessive-compulsive disorder (1991) (32)
Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites (1997) (32)
Biological and behavioral responses to d-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers (1996) (32)
Hybridizing behavioral models: A possible solution to some problems in neurophenotyping research? (2008) (32)
Plasma prolactin stimulation by fenfluramine and amphetamine. (1976) (32)
Clinical, psychophysiological, and neurological characteristics of volunteers with impaired smooth pursuit eye movements (1989) (32)
L-dopa in depressed patients. (1970) (32)
An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice (2013) (31)
Changes in platelet monoamine oxidase activity during abstinence. (1981) (31)
Scopolamine challenges in Alzheimer's disease (2004) (31)
L-dopa, dopamine, and hypomania. (1973) (31)
The Influence of Ondansetron and m-Chlorophenylpiperazine on Scopolamine-Induced Cognitive, Behavioral, and Physiological Responses in Young Healthy Controls (1998) (31)
Enhancement of CO2-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. (1999) (31)
Tranylcypromine Compared with L‐Deprenyl in Alzheimer's Disease (1988) (31)
Temperature, food intake, and locomotor activity effects of a 5-HT3 receptor agonist and two 5-HT3 receptor antagonists in rats (1995) (30)
Therapeutic responses to tricyclic antidepressants and related drugs in non-affective disorder patient populations (1985) (30)
Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder (1994) (30)
Valproate monotherapy in an SRI-intolerant OCD patient. (1998) (30)
CSF somatostatin in obsessive-compulsive disorder. (1993) (30)
Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment (1997) (30)
Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease (2004) (30)
Plasma steady‐state concentrations of hydroxylated metabolites of clomipramine (1982) (30)
Effects of the 5-HT3 Antagonist, Ondansetron, on the Behavioral and Physiological Effects of Pentagastrin in Patients with Panic Disorder and Social Phobia (1997) (29)
Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects (1989) (29)
Neurologic soft signs in obsessive-compulsive disorder. (1991) (29)
High dose naloxone in depression. (1984) (29)
Refining psychiatric genetics: from ‘mouse psychiatry’ to understanding complex human disorders (2008) (28)
A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects (1989) (28)
Screen for MAOA mutations in target human groups. (1999) (28)
Attention dysfunction and psychopathology in college men. (1985) (28)
Cerebrospinal fluid monoamine metabolite levels in human newborn infants born in winter differ from those born in summer (2006) (28)
Parental bonding and hoarding in obsessive-compulsive disorder. (2017) (28)
Diurnal rhythms of serotonin in monkey cerebrospinal fluid. (1982) (28)
Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression. (1992) (28)
Dopamine-β-hydroxylase and norepinephrine in human cerebrospinal fluid: Effects of monoamine oxidase inhibitors (1979) (27)
REM sleep suppression induced by selective monoamine oxidase inhibitors (2004) (27)
Psychological characteristics corresponding to low versus high platelet monoamine oxidase activity. (1979) (27)
Neuronal and Astroglial Responses to the Serotonin and Norepinephrine Neurotoxin: 1-Methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2003) (27)
Functional subsensitivity of 5-HT2A and 5-HT2C receptors mediating hyperthermia following acute and chronic treatment with 5-HT2A/2C receptor antagonists (1997) (27)
A correlation between platelet monoamine oxidase activity and plasma prolactin concentrations in man. (1979) (27)
Lithium does not inhibit the parathyroid hormone-mediated rise in urinary cyclic AMP and phosphate in humans. (1976) (27)
An investigation of doubt in obsessive-compulsive disorder. (2017) (27)
Fluoxetine modulates G protein αs, αq and α12 subunit mRNA expression in rat brain (1992) (26)
Role of the Redox Protein Thioredoxin in Cytoprotective Mechanism Evoked by (-)-Deprenyl (2005) (26)
Comparison of temporal lobe epileptics and affective disorders on the Halstead-Reitan test battery. (1972) (26)
Neurochemical mechanisms in the affective disorders and neuroendocrine correlates. (1981) (26)
Use of narcotic antagonists to study the role of endorphins in normal and psychiatric patients (1979) (26)
Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine. (1983) (25)
MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia. (1978) (25)
Primary affective disorder: thought disorder in depression. (1980) (25)
Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: A preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures (1995) (25)
Separation anxiety disorder in OCD (2011) (24)
N-substituted cyclopropylamines as inhibitors of MAO-A and -B forms. (1978) (24)
Psychological characteristics of subjects identified by platelet MAO activity and evoked potentials as biologically at risk for psychopathology. (1980) (24)
Imaging Elevated Brain Arachidonic Acid Signaling in Unanesthetized Serotonin Transporter (5-HTT)-Deficient Mice (2009) (24)
Open trial of flutamide for treatment of obsessive-compulsive disorder. (1999) (24)
High rates of comorbid OCD in patients with bulimia nervosa (1993) (24)
Hormonal effects of high dose naloxone in humans (1985) (24)
Effects of daily oral m-Chlorophenylpiperazine in elderly depressed patients initial experience with a serotonin agonist (1990) (24)
Phenylethylamine excretion in depression (1984) (24)
The quantitation of manic behavior. (1974) (24)
2-year follow-up of subjects and their families defined as at risk for psychopathology on the basis of platelet MAO activities. 2-year follow-up of low platelet MAO. (1982) (23)
Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression (2018) (23)
Catecholamine metabolism in Gilles de la Tourette's syndrome. (1977) (23)
Indices of noradrenergic output in depression (1986) (23)
Self-stimulation responses are altered following long-term but not short-term treatment with clorgyline (1983) (23)
Social desirability and bipolar affective disorder. (1973) (22)
Clinical and Laboratory Studies with Selective Monoamine-Oxidase-Inhibiting Drugs (1983) (22)
Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments (2004) (22)
Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors (1996) (22)
Technical strategies for the study of catecholamines in man (1973) (22)
Lithium-selective alteration of the function of brain versus cardiac Gs protein (1990) (22)
Catecholamines and indoleamines in patients with Duchenne muscular dystrophy. (1972) (22)
Psychophysical Pain Judgments and Somatosensory Evoked Potentials in Patients with Affective Illness and in Normal Adults (1980) (22)
Long-term antidepressant treatments alter 5-HT2A and 5-HT2C receptor-mediated hyperthermia in Fawn-Hooded rats. (1995) (21)
Developmental alterations in anxiety and cognitive behavior in serotonin transporter mutant mice (2014) (21)
Urinary excretion of 3-methoxy-4-hydroxyphenylglycol in depressed patients: modifications by amphetamine and lithium. (1976) (21)
Symptom exacerbation of vocal tics and other symptoms associated with streptococcal pharyngitis in a patient with obsessive-compulsive disorder and tics. (1998) (21)
Reduction in plasma norepinephrine during fenfluramine treatment (1977) (21)
Seasonal effects on platelet 5-HT content in patients with OCD and controls. (1993) (21)
A new postsynaptic serotonin receptor agonist suitable for studies in humans. (1985) (21)
Perception and cognition in patients with bipolar and unipolar depressive disorders. A study in orschach responding. (1975) (21)
Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. (1985) (20)
Tyramine infusions and selective monoamine oxidase inhibitor treatment (2004) (20)
Differential effects of D- and L-amphetamine on the sleep of depressed patients. (1975) (20)
Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man (1979) (20)
Paranoia and platelet MAO in normals and nonschizophrenic psychiatric groups. (1979) (20)
Down's syndrome (1972) (20)
Serotonergically induced hormonal responses and the antidepressant effect of total sleep deprivation in patients with major depression. (1988) (20)
Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study. (2012) (20)
Obsessive‐Compulsive Disorder: Treatment with Serotonin‐Selective Uptake Inhibitors, Azapirones, and Other Agents (1990) (20)
ADHD and executive functioning deficits in OCD youths who hoard. (2016) (19)
The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. (1985) (19)
Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses (1983) (19)
Abducens palsy after lumbar puncture. (1980) (19)
Psychobiological and pharmacological studies of manic-depressive illness. (1972) (19)
Psychophysiological Changes during Pharmacological Treatment of Patients with Obsessive Compulsive Disorder (1984) (19)
Monoamine metabolites in ‘leftover’ newborn human cerebrospinal fluid — A potential resource for biobehavioral research (1996) (19)
PLASMA DOPAMINE-BETA-HYDROXYLASE IN IDENTICAL TWINS DISCORDANT FOR SCHIZOPHRENIA (1974) (18)
Testmeal Responses Following m-Chlorophenylpiperazine and L-Tryptophan in Bulimics and Controls (1994) (18)
Drug response and psychiatric nosology (1978) (18)
Differences in the preferential deamination of l-norepinephrine, dopamine and serotonin by MAO in rodent and primate brain (1981) (18)
Rebound psychiatric and physical symptoms after gabapentin discontinuation. (1998) (18)
Evidence that 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane-induced hypophagia and hyperthermia in rats is mediated by serotonin-2A receptors. (1994) (18)
The Serotonin Transporter is Required for Stress-Evoked Increases in Adrenal Catecholamine Synthesis and Angiotensin II AT2 Receptor Expression (2003) (18)
Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans (1982) (18)
Effects of reserpine and imipramine on vesicular serotonin uptake and storage in intact human platelets. (1977) (18)
Rare plus common SERT variants in obsessive-compulsive disorder (2007) (17)
Clorgyline treatment differentially affects m-chlorophenylpiperazine-induced neuroendocrine changes. (1988) (17)
Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. (2015) (17)
The role of neurotransmitters and neurohormones in obsessive± compulsive disorder (1997) (17)
Rapid antidepressant effect of addition of lithium to tranylcypromine. (1986) (17)
Mental effects of L-dopa. (1973) (17)
Schizophrenia and platelet monoamine oxidase: research strategies. (1980) (17)
Disturbances of norepinephrine metabolism and alpha-2 adrenergic receptor activity in anorexia nervosa: relationship to nutritional state. (1985) (16)
Genome Wide Association Study (GWAS) between Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD) (2017) (16)
Electrophysiological and receptor studies in rat brain: effects of clorgyline. (1985) (16)
Diurnal rhythms of N-acetylserotonin and serotonin in cerebrospinal fluid of monkeys. (1985) (16)
Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans (1995) (16)
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission. (1993) (16)
Fawn hooded rats are subsensitive to the food intake suppressant effects of 5-HT agonists (2004) (16)
Genome-wide parametric linkage analyses of 644 bipolar pedigrees suggest susceptibility loci at chromosomes 16 and 20 (2008) (16)
Seizure associated with fluoxetine and adjuvant buspirone therapy. (1992) (16)
Intravenous l‐DOPA Plus Carbidopa in Depressed Patients: Average Evoked Response, Learning, and Behavioral Changes (1976) (15)
MMPI differences between unipolar and bipolar depressed subjects: a replication. (1976) (15)
Primary affective disorder: anxiety in unipolar and bipolar depressed groups. (1978) (15)
Monoamine oxidase activity in different density gradient fractions of human platelets (1978) (15)
Antiobsessional and antidepressant effects of clomipramine in the treatment of obsessive-compulsive disorder. (1982) (15)
Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man (1981) (15)
L-dopa, behavioral activation and psychopathology. (1972) (15)
Prolactin response to TRH in Alzheimer's disease and elderly controls (1986) (15)
Lifetime monoamine oxidase inhibition and sleep (1982) (15)
How antidepressants work: cautionary conclusions based on clinical and laboratory studies of the longer-term consequences of antidepressant drug treatment. (1986) (15)
Tricyclic response in obsessive compulsive disorder (1985) (15)
Changes in alpha- and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. (1982) (14)
Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man (1977) (14)
Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. (1982) (14)
Phenelzine in Depressed Patients (1977) (14)
Attenuated response to m-CPP and to pentagastrin after repeated m-CPP in panic disorder (1999) (14)
Clinical studies of monoamine receptors in the affective disorders and receptor changes with antidepressant treatment (1983) (14)
Mood and Behavioral Effects of Physostigmine on Humans Are Accompanied by Elevations in Plasma ??-Endorphin and Cortisol (1981) (14)
Gender-Dependent Modulation of Brain Monoamines and Anxiety-Like Behaviors in Mice with Genetic Serotonin Transporter and BDNF Deficiencies (2006) (14)
Autonomic correlates of sensation seeking and monoamine oxidase activity: using confirmatory factor analysis on psychophysiological data. (1986) (14)
PLATELET MONOAMINE OXIDASE AS A BIOLOGICAL MARKER IN THE AFFECTIVE DISORDERS AND ALCOHOLISM (1982) (14)
M-chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats. (1987) (14)
5‐HT1A RECEPTOR SENSITIVITY IN DEPRESSION AND ANXIETY DISORDERS: MOLECULAR MECHANISMS OF NEUROADAPTION (1992) (14)
Fluoxetine and desipramine selectively attenuate 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine. (1993) (14)
Pharmacological challenge strategies: implications for neurochemical mechanisms in affective disorders and treatment approaches. (1981) (14)
Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. (1983) (14)
Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans (2012) (14)
The role of plasma amine oxidase, platelet monoamine oxidase, and red cell catechol-O-methyl transferase in severe behavioral reactions to disulfiram. (1979) (14)
Effects of parathormone and lithium treatment on calcium and mood in depressed patients. (1977) (14)
Pharmacological and Genetic Characterization of Two Selective Serotonin Transporter Ligands: 2-[2-(Dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-Amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB) (2004) (14)
BEHAVIORAL AND METABOLIC EFFECTS OF L-TRYPTOPHAN IN UNIPOLAR DEPRESSED PATIENTS (1973) (14)
Basal Ganglia MR Relaxometry in Obsessive-Compulsive Disorder: T2 Depends Upon Age of Symptom Onset (2010) (14)
Platelet monoamine oxidase activity in 116 normal rhesus monkeys: relations between enzyme activity and age, sex and genetic factors. (1978) (14)
Catecholamines and Affective Illness: Studies with L-DOPA and Alpha-Methyl-Para-Tyrosine (1971) (13)
Direct sequencing of the reserpine‐sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic depressive illness (1994) (13)
The serotonin agonist, M-chlorophenyl-piperazine, markedly increases levels of plasma catecholamines in the conscious rat (1988) (13)
Extreme elevations in plasma norepinephrine associated with decreased alpha-adrenergic responsiveness in major depressive disorder: two case reports. (1983) (13)
Myoclonus-associated hypomania during MAO-inhibitor treatment. (1980) (13)
Central cholinergic-adrenergic imbalance in the regulation of affective state (1981) (13)
Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat (1985) (13)
Mood-independent aberrancies in associative processes in bipolar affective disorder: An apparent stabilizing effect of lithium (1985) (13)
Physiologic and neuroendocrine responses to intravenous naloxone in subjects with Alzheimer’s disease and age-matched controls (1999) (13)
The Effects of Gender and Gonadal Steroids on the Neuroendocrine and Temperature Response to m-Chlorophenylpiperazine in Leuprolide-induced Hypogonadism in Women and Men (2002) (12)
Low- and high-dose naloxone in dementia of the Alzheimer type. (1985) (12)
Platelet monoamine oxidase activity and life stress as predictors of psychopathology and coping in a community sample (1989) (12)
Tyramine infusions and selective monoamine oxidase inhibitor treatment (2004) (12)
Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. (1994) (12)
Prediction of antidepressant response to lithium carbonate by a 1-day administration of d-amphetamine in unipolar depressed women. (1979) (12)
Self-reported executive function and hoarding in adults with obsessive-compulsive disorder. (2018) (12)
Eye-tracking, attention and amphetamine challenge. (1987) (12)
Genetic deficiencies of monoamine oxidase enzymes: a key to understanding the function of the enzymes in humans. (1998) (12)
The relationship between blood and cerebrospinal fluid prolactin in nonhuman primates. (1982) (12)
THE SEROTONERGIC NEUROTRANSMITTER SYSTEM IN THE AFFECTIVE DISORDERS – A PRELIMINARY EVALUATION OF THE ANTIDEPRESSANT AND ANTIMANIC EFFECTS OF FENFLURAMINE (1978) (12)
High‐Dose Naloxone in Older Normal Subjects: Implications for Alzheimer's Disease (1988) (12)
Elevation of human plasma and platelet amine oxidase activity in response to intravenous dopamine. (1981) (12)
Diurnal variation in cerebrospinal fluid prolactin concentration of the rhesus monkey. (1981) (12)
A biochemical measure of monoamine oxidase type A and B inhibitor effects in man. (1979) (12)
Repetitive TMS as a Probe in Anxiety Disorders: Theoretical Considerations and Case Reports (1997) (11)
Exploring the Association Between Obsessive-Compulsive Symptoms and Loneliness: Consideration of Specificity and Gender (2014) (11)
Changes in human-platelet storage packet size following incubation with labelled serotonin. (1976) (11)
Catecholamines and memory: Enhanced verbal learning during l-DOPA administration (2004) (11)
Denial and somatization as characteristics of bipolar depressed groups. (1980) (11)
A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease (1991) (11)
Long-term antidepressant treatment restores clonidine's effect on growth hormone secretion in a genetic animal model of depression (1995) (11)
(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter (2005) (11)
The central noradrenergic system and affective response to MAO inhibitors. (1979) (11)
Primary Affective Disorder: Bender-Gestalt Sequence of Placement as an Indicator of Impulse Control (1974) (11)
Central and peripheral dopamine beta hydroxylase: Responses to long term treatment with monoamine oxidase inhibitors (1980) (11)
Fluoxetine modulates G protein alpha s, alpha q, and alpha 12 subunit mRNA expression in rat brain. (1992) (11)
Family psychiatric history, cerebrospinal fluid monoamine metabolites, and temperament in infants (1999) (11)
Modulation of vocal and nonvocal behavior in adult squirrel monkeys by selective MAO-A and MAO-B inhibition (1991) (10)
Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients. (1978) (10)
CHAPTER 13 – The Transport of Biogenic Amines (1972) (10)
Effects of serotonin on skeletal muscle growth (2012) (10)
Tyramine infusions in bipolar illness: behavioral effects and longitudinal changes in pressor sensitivity. (1979) (10)
Attenuation of clonidine-induced growth hormone release following chronic glucocorticoid and 5-hydroxytryptamine uptake-inhibiting antidepressant treatments. (1994) (10)
Maximal packet size for serotonin in storage vesicles of intact human platelets. (1978) (10)
Electron probe microanalysis of changes in dense-body phosphorus and calcium content following alterations in platelet serotonin levels. (1979) (10)
Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (2005) (10)
3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid decreases NMDA receptor mRNA. (1992) (10)
Interactions of tricyclic antidepressant drugs with human and rat monoamine oxidase type B (1988) (10)
Using individual items to clarify OCD symptom structure: the case for five factors. (2009) (10)
The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey. (1985) (10)
2′-NH2-MPTP [1-Methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2′-CH3-MPTP [1-Methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine] (2002) (10)
Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline (2004) (10)
Daily administration ofm-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects (1996) (9)
Cerebrospinal fluid hydroxylase cofactor in schizophrenia (1982) (9)
Preferential accumulation of lithium in the dense bodies of human platelets. (1982) (9)
Long-term imipramine treatment differentially affects fenfluramine-induced suppression of food intake and locomotor activity (1988) (9)
Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease (2004) (9)
Animal Models for Human Psychopathology (1976) (9)
Brain and liver monoamine oxidase type A and type B activity in alcoholics and controls. (1985) (9)
An 18-month followup of students biologically at risk for psychiatric problems. (1980) (9)
An overview of serotonin neurochemistry and neuroanatomy (1991) (9)
Sleep disturbance in depression: diagnostic potential and pathophysiology [proceedings]. (1980) (9)
Biological alterations in the primary affective disorders and other tricyclic-responsive disorders (1985) (9)
Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity (2005) (8)
Clinical correlates and genetic linkage of social and communication difficulties in families with obsessive–compulsive disorder: Results from the OCD Collaborative Genetics Study (2014) (8)
Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice (2017) (8)
Childhood obsessive-compulsive disorder. (1981) (8)
Relationships between platelet and plasma monoamine oxidase, plasma dopamine-beta-hydroxylase, and urinary 3-methoxy-4-hydroxy phenylglycol. (1975) (8)
Selective amine oxidase inhibitors: basic to clinical studies and back. (1987) (8)
Biological Factors in the Affective Disorders and Schizophrenia (1974) (8)
Dysregulation of 5‐HT Function in Bulimia Nervosa (1989) (8)
Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase (2005) (8)
Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase (1996) (8)
Phenylethylamine, Tyramine and Other Trace Amines in Patients with Affective Disorders: Associations with Clinical State and Antidepressant Drug Treatment (1984) (7)
Principles of Psychiatric Genetics: Genetic contributions to obsessive–compulsive disorder (OCD) and OCD-related disorders (2012) (7)
A comparison between the growth hormone responses to amphetamine and clonidine (1985) (7)
PSYCHOLOGICAL AND PHYSIOLOGICAL CORRELATES OF VARIATIONS IN SMOOTH PURSUIT EYE MOVEMENTS (1982) (7)
NOREPINEPHRINE AND SEROTONIN METABOLISM IN THE RAT BRAIN: EFFECTS OF CHRONIC PHENELZINE ADMINISTRATION (1978) (7)
How memory fails: A theoretical model (1985) (7)
PSYCHOACTIVE DRUG EFFECTS ON PLASMA NOREPINEPHRINE AND PLASMA DOPAMINE β-HYDROXYLASE IN MAN (1979) (7)
Plasma levels of m-chlorophenylpiperazine following single oral dose administration of m-chlorophenylpiperazine and trazodone in human volunteers (1997) (7)
Brucellosis in Irish meatworkers. (1979) (7)
Design and interpretation of opiate antagonist trials in dementia (1986) (7)
Brain serotonin subsystem complexity and receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists. (1993) (7)
Evaluation of alpha-adrenergic responsiveness to clonidine challenge and noradrenergic metabolism in the affective disorders and their treatment. (1982) (7)
Individual differences in average evoked responses to d- and l-amphetamine with and without lithium carbonate in depressed patients (1977) (7)
Hypervigilance in patients with obsessive-compulsive disorder. (1996) (7)
Effects of drug states and clinical phenomena on the storage and retrieval of information in man [proceedings]. (1977) (7)
Adrenergic and Noradrenergic Plasma Levels in Lesch-Nyhan Disease (2000) (7)
Interaction between cytosolic monoamine oxidase and spin-labeled amphetamine and its modification by clorgyline and pargyline. (1983) (7)
Differential effects of antidepressant treatments on fenfluramine-induced increases in plasma prolactin and corticosterone in rats (1991) (7)
Serotonin neurochemistry: A commentary on some of its quandaries (1986) (7)
TOTAL BODY POTASSIUM CHANGES DURING LITHIUM ADMINISTRATION (1971) (6)
Enhanced anorexic responses to m-chlorophenylpiperazine during lithium administration to Fawn-Hooded rats (1994) (6)
Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases (1982) (6)
Long-term imipramine treatment potentiates m-chlorophenylpiperazine-induced changes in prolactin but not corticosterone or growth hormone levels in rats (1989) (6)
ACUTE ADMINISTRATION OF ONDANSETRON AND M‐CPP IN HEALTHY VOLUNTEERS: BEHAVIORAL AND BIOLOGICAL RESULTS (1992) (6)
NEUROLOGIC SOFT SIGNS IN OBSESSIVE-COMPULSIVE DISORDER. AUTHOR'S REPLY (1991) (6)
Dopamine-beta-hydroxylase and norepinephrine in human cerebrospinal fluid: effects of monoamine oxidase inhibitors. (1979) (6)
Norepinephrine in the Affective Disorders: Receptor Assessment Strategies (1985) (6)
Involvement of the central serotonergic system in affective illness. (1981) (6)
[Fenfluramine and its effects on the sympathetic nervous system in man (author's transl)]. (1980) (6)
Differential effects of long-term lithium and carbamazepine administration on Gs alpha and Gi alpha protein in rat brain. (1991) (6)
Brain-Derived Neurotrophic Factor, Serotonin Transporter, and Depression: Comment on Kaufman et al (2007) (6)
Dependent personality, separation anxiety disorder and other anxiety disorders in OCD. (2016) (6)
Primary affective disorder: delineation of a unipolar depressive subtype. (1973) (6)
Role of serotonergic input in the down-regulation of beta-adrenoceptors following long-term clorgyline treatment. (1988) (6)
Repeated administration of meta-chlorophenylpiperazine or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane produces tolerance to its stimulatory effect on adrenocorticotropin hormone but not prolactin or corticosterone secretion in rats. (1996) (6)
Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon? (1998) (6)
Analysis of MAOA mutations in humans. (1995) (5)
Anxiolytic effects of drugs acting on 5-HT receptor subtypes (1992) (5)
Circadian variation in the CSF cortisol concentration of the rhesus monkey. (1980) (5)
Long-term desipramine treatment attenuates clonidine-induced suppression of ventral tegmental self-stimulation. (1985) (5)
Behavioral Genetics of the Mouse: Behavioral phenotyping of mouse grooming and barbering (2013) (5)
Platelet monoamine oxidase activity and human sleep. (1978) (5)
Differential effect of clomipramine treatment on m-chlorophenylpiperazine-induced increases in plasma prolactin and corticosterone in rats (1989) (5)
Lack of the serotonin transporter does not prevent mineralocorticoid hypertension in rat and mouse. (2008) (5)
Platelet monoamine oxidase activity and clomipramine-induced mania in unipolar depressed patients. (1980) (5)
Lithium and mood change in affective disorder patients. (1981) (5)
Alterations in Human-Platelet Serotonin Uptake Following the Addition of Thrombin or A 23187 (1977) (5)
Long-term lithium treatment in rats attenuates m-chlorophenylpiperazine-induced decreases in food intake but not locomotor activity (2004) (5)
Self-reported depression in bipolar groups (1983) (5)
Lithium treatment restores clonidine's effect in an animal model of depression (1994) (5)
Effects of antimycin A plus 2-deoxyglucose on uptake and vesicular storage of serotonin in human platelets. (1978) (5)
Family history of depression and alcoholism in Alzheimer patients and age‐matched controls (1989) (4)
CHOLINERGIC-β-ENDORPHIN HYPERSENSITIVITY ASSOCIATED WITH DEPRESSION (1982) (4)
A pilot study of serotonergic system responsivity in Alzheimer's disease. (1988) (4)
Serotonin in Major Psychiatric Disorders (Progress in Psychiatry Series) (1991) (4)
Hormonal Responses to Serotonergic Drugs as a Means to Evaluate Brain Serotonergic Function in Humans (1990) (4)
Thyroid disease and dementia of the Alzheimer type. (1988) (4)
Applicability of models for carrier‐mediated serotonin transport to pools of serotonin in intact human platelets. (1981) (4)
Abnormal protein in the cerebrospinal fluid of patients with a submicroscopic X-chromosomal deletion associated with Norrie disease: preliminary report. (1991) (4)
Monoamine oxidase inhibitors (MAOI) increase rat brain aromatic amino acid decarboxylase activity. (1980) (4)
The Origin, Drug Interaction, Urine, Plasma and CSF Concentrations of Phenylacetic Acid in Normal and Psychiatric Subjects (1984) (4)
Serotoninergic Function in Neuropsychiatric Disorders (1989) (4)
Neuroendocrine Responses to Serotonin Agonists as Possible Markers of the Functional State of Serotonergic Neurotransmission in Psychiatric Disorders (1985) (4)
Cardiovascular changes accompanying MAO inhibition in man (1981) (4)
Alterations in noradrenergic function during clorgyline treatment. (1980) (4)
Biphasic effects of metergoline in fluoxetine-treated OCD patients (1994) (4)
Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone (2004) (4)
Thyrotropin-releasing hormone and dementia. (1986) (4)
Differential effect of short- and long-term lithium treatment on m-CPP-induced neuroendocrine changes in rats. (1993) (3)
Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study (1987) (3)
The Genetics of Anxiety (2009) (3)
Marked enhancement by clorgyline of nocturnal and daytime melatonin release in rhesus monkeys (2004) (3)
Proceedings: Monoamine oxidase in man: enzyme characteristics in human platelets, plasma, and other human tissues. (1974) (3)
Neurobiological Considerations of the mode of action of lithium carbonate in the treatment of affective disorders? (1976) (3)
Phenylethylamine Deamination in the Noradrenergic Neurotransmitter System (1984) (3)
The need for early markers in Alzheimer’s disease (1990) (3)
PHENYLETHYLAMINE (PEA) AND CHRONIC SCHIZOPHRENIA (1979) (3)
partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects (1999) (3)
The NMDA receptor complex modulates clonidine-induced increases in growth hormone levels in rats (1995) (3)
Differential effect of lithium treatment on fenfluramine-induced decreases in food intake and locomotor activity in rats (1991) (3)
497. Mechanism of efficacy of fluoxetine in premenstrual syndrome (1996) (3)
General personality dimensions, impairment and treatment response in obsessive-compulsive disorder. (2019) (2)
Immunologic function in man receiving lithium carbonate. (1978) (2)
Obsessionalism and response to lithium. (1979) (2)
A Reevaluation of Biogenic Amines in Manic and Depressive States (1972) (2)
Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y (1989) (2)
Storage and recall of verbal and pictorial information (1976) (2)
Trace Indoleamines in the Central Nervous System (1985) (2)
Transcranial Magnetic Stimulation as a Probe and Potential Treatment in Obsessive-Compulsive Disorder (1998) (2)
Neurotransmitter-related enzymes in the major psychiatric disorders: II. MAO and DBH in schizophrenia. (1975) (2)
Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition (2004) (2)
Clinical, Genetic, Hormonal and Drug Influences on the Activity of Human Platelet Monoamine Oxidase (2008) (2)
Platelet mao activity in alzheimer patients, older depressives, and age-matched controls (1989) (2)
Effect of Phenoxybenzamine on Phagocytic Activity and Shock Mortality in the Rat.∗ (1964) (2)
Effects of lithium on catecholamines and other brain neurotransmitters. (1976) (2)
NMDA receptor antagonists block development of tolerance to m-CPP-induced increases in ACTH concentrations in rats. (1996) (2)
Phenelzine in depressed patients. Effects on urinary MHPG excretion in relation to clinical response. (1977) (2)
6-Hydroxydopamine pretreatment effects on α- and β-adrenergic receptor adaptation to clorgyline (1985) (2)
PLATELET MONOAMINE OXIDASE AND CORTICAL EVOKED POTENTIALS AS PREDICTORS OF PSYCHIATRIC VULNERABILITY (1979) (2)
Physiological Effects of High Dose Naloxone Administration to Normal Adults (1983) (2)
Prediction of antidepressant responses to imipramine. (1979) (2)
Obsessive-compulsive disorder and its treatment with serotonin-selective agents. (1990) (1)
Cerebrospinal Fluid and Behavioral Changes After Methyltestosterone Administration (2015) (1)
Are Effective Antiobsessional Drugs Interchangeable?-Reply (1991) (1)
20-NH2-MPTP: A Serotonin and Norepinephrine Neurotoxin (2014) (1)
Clinical and pharmacological investigations of the psychobiology of the affective disorders. (1971) (1)
Neurotransmitter-related enzymes in the major psychiatric disorders: I. Catechol-O-methyl transferase, monoamine oxidase in the affective disorders, and factors affecting some behaviorally correlated enzyme activities. (1975) (1)
Comparative Evaluation of a Platelet Serotonin Assay Utilizing Ortho-Phthaldialdehyde for Fluorophore Production (1975) (1)
Affective, behavioral, and other non-endocrine physiologic responses to 5-HT 1 2 agonists and antagonists in humans (1993) (1)
A preliminary study of the effects of m-CPP on sleep architecture and behavior in healthy volunteers (1989) (1)
285. Differential activation of ZIF268 in the amygdala in response to mCPP (1996) (1)
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype (2003) (1)
The Importance of a Clinical Perspective-Reply (1984) (1)
Seasonal Variation in Behavioral m-CPP in Patients with Seasonal Disorder and Controls Responses Affective to (1993) (1)
heterogeneityas an example of overlapping clinical and genetic compulsive - and other neurotransmitter systems: obsessive Anxiety and affective disorder comorbidity related to serotonin (2014) (1)
BIOLOGIC MARKERS FOR SEROTONERGIC DYSFUNCTION IN PSYCHIATRIC DISORDERS (1984) (1)
ReviewArticle The Importance of Cognitive Phenotypes in Experimental Modeling of Animal Anxiety and Depression (2007) (1)
Starting with serotonin: How a high-rolling father of drug discovery repeatedly beat the odds (2008) (1)
Hyperlocomotion induced by dopamine or cholecystokinin + dopamine in the nucleus accumbens is not modified by chronic lithium treatment (1989) (1)
Recent Developments Regarding the Use of Monoamine Oxidase Inhibitors in Psychopharmacology (1984) (1)
Differential effects of clorgyline on noradrenergic vs serotonergic systems in man (1982) (1)
Comparison of the X537A-induced ionophoric removal of serotonin and tryptamine from intact human platelets. (1978) (1)
Chapter 5. Biological Factors in the Major Psychoses (1975) (1)
Adenosine A1 and A2A receptors in serotonin transporter deficient mice (1999) (1)
Schizophrenia and publication: epilogue. (1978) (1)
Screening young adults for psychiatric vulnerability: a preliminary comparison of biological and clinical measures. (1979) (1)
Biochemistry — “High Risk” Predictor (1977) (1)
Failure of high dose naloxone to relieve tardive dyskinesia. (1987) (1)
Chapter 5: Biological Factors in Psychiatric Disorders (1976) (0)
LONG‐TERM ANTIDEPRESSANT DRUG TREATMENT DIFFERENTIALLY MODULATES G&agr; SUBUNIT mRNA AND PROTEIN EXPRESSION IN RAT BRAIN (1992) (0)
NIMH Dementia Mood Assessment Scale (DMAS) 1988 (2004) (0)
Experimental Investigation of the Serotonin Hypothesis of Aggressive Behavior (1999) (0)
Treatment of Hyperactive Children With (2015) (0)
Elevated Phenylethylamine Excretion in Women (1985) (0)
4-2 Gonadal steroids and serotonin: Development and treatment of mood disorders (1997) (0)
An antibody to nerve growth factor in Alzheimer's disease (1987) (0)
Response (1987) (0)
Serotonin neurochemistry and psychopharmacology in 1986 (1987) (0)
Letter: Lithium treatment for amphetamine abuse. (1974) (0)
Dr. Siever and Associates Reply (2006) (0)
6-Hydroxydopamine pretreatment effects on alpha- and beta-adrenergic receptor adaptation to clorgyline. (1985) (0)
Research nqofi Gene s*mcture and 5'~flanking regulatory region of the murine serotonin transporter (1997) (0)
Affective illness: two decades of psychobiological investigations. (1992) (0)
Radiotelemetry in Cardiovascular Chronopharmacology in Transgenic and Knock- out Rats and Mice (2013) (0)
A Pilot Study of Intravenous Thyrotropin‐Releasing Hormone in Alzheimer's Disease (1989) (0)
THE SOMATIZATION SPECTRUM AND ANTIDEPRESSANT RESPONSE IN THE MEDICALLY ILL (1992) (0)
The effect of lithium on thyroid iodine release in patients with primary affective disorder (1974) (0)
BIOLOGIC MARKERS IN DSM-III DIAGNOSED PERSONALITY DISORDERS (1984) (0)
ImpairedStress-CopingandFearExtinctionandAbnormal CorticolimbicMorphologyinSerotoninTransporter Knock-OutMice (2007) (0)
Monoamine Oxidase, Monoamine-Oxidase-Inhibiting Drugs, and Human Behavior (1987) (0)
Serotonergic mechanisms in Alzheimer's disease and normal aging (1989) (0)
Decreases in dhea in Alzheimer's disease: A possible new therapeutic strategy (1989) (0)
256. The serotonin transporter gene influences seasonality independently of personality (2000) (0)
Down's Syndrome: Transport, Storage, and Metabolism of Serotonin in Blood Platelets (1972) (0)
THE DIURNAL RHYTHM IN CORTICOTROPIN RELEASING HORMONE IS INVERSELY RELATED TO THAT OF CORTISOL IN PRIMATE CEREBROSPINAL-FLUID (1987) (0)
Alzheimer's disease. How memory fails: a theoretical model. (1985) (0)
465. Personality traits are correlated with motor cortex excitability: a transcranial magnetic stimulation (TMS) study (2000) (0)
Advances in obsessive-compulsive disorder research. (1981) (0)
OCD: Perspectives on the Next Millennium From the Adult OCD Research Unit, NIMH Intramural Research Program (1998) (0)
Uptake inhibitors selectively attenuate depletions in cortical and hippocampal serotonin and norepinephrine caused by 2-NH-2-MPTP in two strains of mice (1993) (0)
Response (1994) (0)
Response to julio pascual regarding Kishore-Kumar et al Pain, 37 (1989) 223–227 (1990) (0)
Experimental Models in Serotonin Transporter Research: Modeling SERT × BDNF interactions in brain disorders: single BDNF gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities in serotonin transporter knock-out mice (2010) (0)
Monoamine Oxidase (MAO) Inhibitors in Psychiatric Therapy (1989) (0)
Influence of the serotonin antagonist, metergoline, on anxiogenic and neuroendocrine effects of carbon dioxide in healthy volunteers (1999) (0)
SEASONAL AFFECTIVE DISORDER, LIGHT THERAPY, AND THE SEROTONIN SYSTEM (1994) (0)
The serotonin connection in OCD. Comments on "Recent advances in obsessive-compulsive disorder". (1991) (0)
Letter: Glutamate decarboxylation in human platelets. (1974) (0)
Separation and Depression: Clinical and Research Aspects, edited by John Paul Scott and Edward C. Senay. Washington, D.C., American Association for the Advancement of Science, 1973, 245 pp., $19.95 (1974) (0)
A comparison of neuroendocrine responses to L-TRP and m-CPP in bulimics and controls (1989) (0)
Mode of action of Li in treating affective disorders-neurobiological considerations. (1976) (0)
Pre- and post-partum plasma amine oxidase differences in the rhesus monkey (Macaca mulatta) (1976) (0)
Abnormal intestinal function in mice lacking the serotonin reuptake transporter (SERT) (2000) (0)
Positive experiences in bipolar patients. (1980) (0)
P-2-124 Plasma concentration of MCPP after single oral dose administration of trazodone and MCPP in humans (1995) (0)
Manic State Rating Scale 1971 (1995) (0)
PLATELET NEUROTRANSMITTER – RELATED ENZYMES IN PSYCHO – PHARMACOLOGIC STUDIES (1981) (0)
Drs. Siever and Murphy Reply (1986) (0)
Correction: Behavioral and synaptic alterations relevant to obsessivecompulsive disorder in mice with increased EAAT3 expression (2019) (0)
Serotonin in Major Psychiatric (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dennis L. Murphy?

Dennis L. Murphy is affiliated with the following schools:

University of Maryland, College Park

Dennis L. Murphy's Academic­Influence.com Rankings

Dennis L. Murphy's Degrees

Why Is Dennis L. Murphy Influential?

Dennis L. Murphy's Published Works

Published Works

What Schools Are Affiliated With Dennis L. Murphy?

Dennis L. Murphy's AcademicInfluence.com Rankings